Business

Bavarian Nordic A/S : - Transactions in Connection with Share Buy-Back Program

Bavarian Nordic A/S : - Transactions in Connection with Share Buy-Back

Bavarian Nordic A/sApril 13, 20264
Bavarian Nordic A/S : - Transactions in Connection with Share Buy-Back Program

About this update from Bavarian Nordic A/s

Danish English Published: 2026-04-13 08:45:39 CEST Bavarian Nordic A/S - Changes in company's own shares Bavarian Nordic - Transactions in Connection with Share Buy-Back Program COPENHAGEN, Denmark, April 13, 2026 - Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation. Since the last announcement of transactions on April 7, 2026, the following transactions have been made by Nordea on behalf of Bavarian Nordic: Number of shares Average purchase price, DKK Transaction value, DKK Accumulated until April 7, 2026 399,635 186.33 74,465,587 April 7, 2026 65,000 194.88 12,667,499 April 8, 2026 10,110 197.39 1,995,655 April 9, 2026 33,007 193.58 6,389,578 April 10, 2026 6,500 197.00 1,280,512 Accumulated under the program 514,252 188.23 96,798,831 The details for each transaction made under the share repurchase program are published on bavarian-nordic.com . Following these transactions, Bavarian Nordic holds a total of 2,212,013 treasury shares, corresponding to 2.79% of the Company's share capital. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit https://www.bavarian-nordic.com Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Disa Tuominen, IR Manager, [email protected] US: Graham Morrell, Gilmartin Group, [email protected] , Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, [email protected] , Tel: +45 53 88 06 03 Company Announcement no. 17 / 2026 Attachments Bavarian Nordic - Transactions in Connection with Share Buy-Back Program Appendix with detailed transaction data 2026-17-en.pdf https://attachment.news.eu.nasdaq.com/ae25147b12ab9eba933e20b797080df06 2026-17-appendix-en.pdf https://attachment.news.eu.nasdaq.com/a83a867c52b7088a64949bd1eb09e71d9 Company News Subscribe European Market Activity Nasdaq Europe © 2025, Nasdaq, Inc. All Rights Reserved.

View stock analysis, news, and events for Bavarian Nordic A/s

More from Bavarian Nordic A/s

All Bavarian Nordic A/s news →